| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 19 | 2024 | 534 | 3.540 |
Why?
|
| Tumor Microenvironment | 8 | 2025 | 179 | 3.100 |
Why?
|
| Neoplasms | 6 | 2025 | 818 | 1.960 |
Why?
|
| Macrophages | 5 | 2020 | 296 | 1.870 |
Why?
|
| Carcinoma, Pancreatic Ductal | 6 | 2024 | 135 | 1.740 |
Why?
|
| Cachexia | 4 | 2020 | 53 | 1.560 |
Why?
|
| Mucin-1 | 5 | 2024 | 35 | 1.260 |
Why?
|
| Cathepsins | 1 | 2025 | 4 | 0.950 |
Why?
|
| Myeloid Cells | 1 | 2024 | 28 | 0.860 |
Why?
|
| Signal Transduction | 11 | 2025 | 1433 | 0.840 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 32 | 0.810 |
Why?
|
| Immunoglobulin E | 2 | 2021 | 19 | 0.810 |
Why?
|
| Gallic Acid | 2 | 2013 | 9 | 0.790 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 451 | 0.780 |
Why?
|
| Animals | 20 | 2025 | 10416 | 0.770 |
Why?
|
| Deoxycytidine | 4 | 2021 | 66 | 0.770 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 465 | 0.750 |
Why?
|
| Glycolysis | 5 | 2019 | 85 | 0.730 |
Why?
|
| Cholesterol | 4 | 2025 | 200 | 0.710 |
Why?
|
| Atherosclerosis | 1 | 2022 | 96 | 0.700 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 297 | 0.680 |
Why?
|
| Tumor Escape | 1 | 2020 | 11 | 0.680 |
Why?
|
| STAT3 Transcription Factor | 2 | 2020 | 98 | 0.670 |
Why?
|
| Mice | 14 | 2024 | 4655 | 0.670 |
Why?
|
| Muscle, Skeletal | 3 | 2020 | 634 | 0.630 |
Why?
|
| Humans | 29 | 2025 | 28167 | 0.620 |
Why?
|
| Immunotherapy | 1 | 2020 | 158 | 0.590 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2025 | 65 | 0.580 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 3 | 0.570 |
Why?
|
| Poly I-C | 1 | 2017 | 10 | 0.570 |
Why?
|
| Polylysine | 1 | 2017 | 14 | 0.570 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2025 | 126 | 0.570 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 38 | 0.560 |
Why?
|
| Energy Metabolism | 2 | 2021 | 198 | 0.500 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 329 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 411 | 0.450 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 12 | 0.420 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 121 | 0.390 |
Why?
|
| Spleen | 2 | 2024 | 112 | 0.390 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2020 | 50 | 0.380 |
Why?
|
| Culture Media, Conditioned | 3 | 2020 | 31 | 0.380 |
Why?
|
| Pistacia | 1 | 2011 | 3 | 0.370 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2011 | 20 | 0.370 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 26 | 0.370 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 58 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 1573 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 2 | 2025 | 135 | 0.360 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 1327 | 0.360 |
Why?
|
| Cell Line | 4 | 2020 | 694 | 0.360 |
Why?
|
| Cell Adhesion | 1 | 2011 | 138 | 0.360 |
Why?
|
| Plant Extracts | 1 | 2011 | 64 | 0.350 |
Why?
|
| Neoplasm Proteins | 2 | 2023 | 123 | 0.320 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 270 | 0.320 |
Why?
|
| Mice, Transgenic | 3 | 2020 | 509 | 0.310 |
Why?
|
| Immunity, Innate | 2 | 2022 | 225 | 0.300 |
Why?
|
| MicroRNAs | 1 | 2012 | 299 | 0.290 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2025 | 28 | 0.240 |
Why?
|
| Tetraspanins | 1 | 2025 | 54 | 0.230 |
Why?
|
| Capillary Permeability | 1 | 2025 | 53 | 0.230 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 6 | 0.230 |
Why?
|
| Glucose | 3 | 2017 | 203 | 0.230 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2017 | 60 | 0.230 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 50 | 0.220 |
Why?
|
| Hydrolases | 1 | 2024 | 11 | 0.220 |
Why?
|
| Immune Evasion | 1 | 2024 | 8 | 0.220 |
Why?
|
| Muscular Atrophy | 2 | 2020 | 31 | 0.220 |
Why?
|
| Antigen Presentation | 1 | 2024 | 78 | 0.220 |
Why?
|
| Cells, Cultured | 2 | 2020 | 985 | 0.210 |
Why?
|
| Cell Membrane | 1 | 2025 | 260 | 0.210 |
Why?
|
| Anoctamin-1 | 1 | 2023 | 3 | 0.210 |
Why?
|
| Dendritic Cells | 1 | 2024 | 143 | 0.210 |
Why?
|
| Hypoxia | 1 | 2024 | 89 | 0.200 |
Why?
|
| Enzyme Inhibitors | 2 | 2024 | 250 | 0.190 |
Why?
|
| Endothelial Cells | 1 | 2025 | 362 | 0.190 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2022 | 6 | 0.190 |
Why?
|
| Mammals | 1 | 2022 | 48 | 0.180 |
Why?
|
| Sirtuins | 1 | 2021 | 17 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2021 | 84 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 315 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 48 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 65 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 120 | 0.180 |
Why?
|
| NADPH Oxidase 4 | 1 | 2020 | 8 | 0.170 |
Why?
|
| Leucovorin | 1 | 2020 | 19 | 0.170 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 42 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2020 | 58 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 33 | 0.170 |
Why?
|
| Splenectomy | 1 | 2020 | 44 | 0.170 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 41 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 38 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 114 | 0.170 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 100 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 116 | 0.160 |
Why?
|
| Pancreatectomy | 1 | 2020 | 58 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 73 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2020 | 76 | 0.160 |
Why?
|
| Pancreas | 1 | 2020 | 61 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2020 | 103 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 42 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 238 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 302 | 0.160 |
Why?
|
| Farnesyltranstransferase | 1 | 2019 | 1 | 0.160 |
Why?
|
| Metabolome | 2 | 2020 | 68 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 215 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2019 | 77 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 283 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 1462 | 0.140 |
Why?
|
| Arginase | 1 | 2018 | 6 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2018 | 40 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 23 | 0.140 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 28 | 0.140 |
Why?
|
| Cytokines | 1 | 2020 | 446 | 0.140 |
Why?
|
| Inflammation | 1 | 2021 | 633 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 284 | 0.130 |
Why?
|
| Survival Rate | 1 | 2017 | 430 | 0.130 |
Why?
|
| Silymarin | 1 | 2015 | 6 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 167 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 327 | 0.120 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2014 | 3 | 0.110 |
Why?
|
| United States | 1 | 2020 | 2151 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 608 | 0.110 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 36 | 0.110 |
Why?
|
| Autophagy | 1 | 2014 | 71 | 0.100 |
Why?
|
| Hydrogen Peroxide | 1 | 2013 | 144 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 276 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2013 | 156 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2012 | 658 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2014 | 578 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 135 | 0.100 |
Why?
|
| Cell Survival | 1 | 2014 | 408 | 0.100 |
Why?
|
| Crops, Agricultural | 1 | 2012 | 19 | 0.090 |
Why?
|
| Exome | 1 | 2012 | 31 | 0.090 |
Why?
|
| Plant Tumors | 1 | 2011 | 1 | 0.090 |
Why?
|
| Chromatography, Thin Layer | 1 | 2011 | 18 | 0.090 |
Why?
|
| Chemical Fractionation | 1 | 2011 | 9 | 0.090 |
Why?
|
| Plants, Medicinal | 1 | 2011 | 18 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 50 | 0.090 |
Why?
|
| Plants | 1 | 2012 | 68 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 55 | 0.090 |
Why?
|
| Plant Leaves | 1 | 2011 | 57 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 131 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 258 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2019 | 330 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 180 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2025 | 847 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 369 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2021 | 61 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 49 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 190 | 0.080 |
Why?
|
| Pentose Phosphate Pathway | 3 | 2017 | 11 | 0.080 |
Why?
|
| Neutrophils | 1 | 2011 | 181 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2014 | 522 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 513 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2013 | 485 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 406 | 0.080 |
Why?
|
| Disease Progression | 2 | 2021 | 474 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2021 | 110 | 0.070 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2007 | 3 | 0.070 |
Why?
|
| Time Factors | 1 | 2011 | 1593 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Asthma | 1 | 2007 | 60 | 0.060 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2025 | 16 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2025 | 24 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2025 | 33 | 0.060 |
Why?
|
| Simvastatin | 1 | 2025 | 24 | 0.060 |
Why?
|
| Female | 6 | 2021 | 15191 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 75 | 0.060 |
Why?
|
| Quinaldines | 1 | 2024 | 5 | 0.060 |
Why?
|
| Proteins | 1 | 2007 | 252 | 0.060 |
Why?
|
| Quinoxalines | 1 | 2024 | 17 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2024 | 50 | 0.060 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2024 | 10 | 0.060 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 22 | 0.060 |
Why?
|
| Male | 3 | 2021 | 13510 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 58 | 0.060 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 31 | 0.060 |
Why?
|
| Polyamines | 1 | 2024 | 13 | 0.060 |
Why?
|
| Acetyltransferases | 1 | 2024 | 36 | 0.050 |
Why?
|
| Apoptosis | 2 | 2019 | 774 | 0.050 |
Why?
|
| Aspartate Aminotransferase, Cytoplasmic | 1 | 2021 | 6 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2021 | 9 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2021 | 267 | 0.040 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 7 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 43 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 35 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 187 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 191 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 25 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 363 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 18 | 0.040 |
Why?
|
| Gels | 1 | 2019 | 28 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 104 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2020 | 184 | 0.040 |
Why?
|
| U937 Cells | 1 | 2018 | 8 | 0.040 |
Why?
|
| Nanostructures | 1 | 2019 | 64 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 179 | 0.040 |
Why?
|
| Cell Separation | 1 | 2018 | 55 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 90 | 0.040 |
Why?
|
| Cell Count | 1 | 2018 | 86 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2018 | 35 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2018 | 93 | 0.040 |
Why?
|
| Polymers | 1 | 2019 | 117 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 133 | 0.030 |
Why?
|
| Digoxin | 1 | 2017 | 8 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 849 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 288 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2017 | 126 | 0.030 |
Why?
|
| Carbon | 1 | 2017 | 108 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 44 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 123 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 803 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 248 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 194 | 0.030 |
Why?
|
| Antioxidants | 1 | 2015 | 225 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 211 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 176 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 284 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 678 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 354 | 0.030 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2012 | 14 | 0.020 |
Why?
|
| Ketoglutaric Acids | 1 | 2012 | 16 | 0.020 |
Why?
|
| Glutamine | 1 | 2012 | 32 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 453 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 806 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 690 | 0.020 |
Why?
|
| Citric Acid Cycle | 1 | 2012 | 15 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 36 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 49 | 0.020 |
Why?
|
| Plant Physiological Phenomena | 1 | 2012 | 19 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1052 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 124 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 61 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 77 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 345 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 465 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 663 | 0.020 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 353 | 0.020 |
Why?
|
| Child | 1 | 2007 | 2253 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 3128 | 0.010 |
Why?
|
| Adult | 1 | 2007 | 7765 | 0.010 |
Why?
|